|
|
 Previous Article | Table of Contents | Next Article 
Detection of residual leukemia after bone marrow transplant for chronic
myeloid leukemia: role of polymerase chain reaction in predicting relapse
TP Hughes, GJ Morgan, P Martiat and JM Goldman
MRC/LRF Leukaemia Unit, Royal Postgraduate Medical School, London, UK.
We used the polymerase chain reaction (PCR) to detect residual leukemia-
specific mRNA in blood and marrow from 37 patients in complete hematologic
and cytogenetic remission after allogeneic bone marrow transplant (BMT) for
chronic myeloid leukemia (CML). Our two-step PCR method involved the use of
"nested primers" in the second step and could detect one K562 cell diluted
into 10(5) normal cells. Elaborate measures were taken to exclude
false-positive and false-negative results. In nine patients whose blood and
marrow were studied simultaneously the results were concordant (two
positive and seven negative). Twenty-three patients transplanted in chronic
phase (CP) with unmanipulated donor marrow were studied. Blood cells from
nine of these patients were studied 3 to 6 months post-BMT and six were PCR
positive; three were negative on subsequent studies. Blood cells from 18
patients studied between 8 months and 8 years post-BMT were all PCR
negative. Nine patients transplanted in CP with T-cell-depleted marrow
cells were studied. Blood from five was positive 3 to 24 months post- BMT;
blood from five was negative 3 to 6 years post-BMT. Four patients no longer
in first CP were studied after BMT with unmanipulated donor marrow. Blood
from all four was positive 5 to 19 months post-BMT. Based on the known
clinical results of transplant in these three cohorts we conclude that PCR
may be positive within 6 months of BMT in patients who can expect
long-lasting remission, whereas PCR positivity later after BMT may indicate
that the probability of cure is reduced. Thus, the technique may prove
useful for early assessment of new transplant protocols that might
inadvertently increase the risk of relapse.
Volume 77,
Issue 4,
pp. 874-878,
02/15/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Hughes, M. Deininger, A. Hochhaus, S. Branford, J. Radich, J. Kaeda, M. Baccarani, J. Cortes, N. C. P. Cross, B. J. Druker, et al.
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Blood,
July 1, 2006;
108(1):
28 - 37.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Robien, C. M. Ulrich, J. Bigler, Y. Yasui, T. Gooley, B. Bruemmer, J. D. Potter, and J. P. Radich
Methylenetetrahydrofolate Reductase Genotype Affects Risk of Relapse after Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia
Clin. Cancer Res.,
November 15, 2004;
10(22):
7592 - 7598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. P. Hughes, J. Kaeda, S. Branford, Z. Rudzki, A. Hochhaus, M. L. Hensley, I. Gathmann, A. E. Bolton, I. C. van Hoomissen, J. M. Goldman, et al.
Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
N. Engl. J. Med.,
October 9, 2003;
349(15):
1423 - 1432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bagg
Chronic Myeloid Leukemia: A Minimalistic View of Post-Therapeutic Monitoring
J. Mol. Diagn.,
February 1, 2002;
4(1):
1 - 10.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Druker, S. G. O'Brien, J. Cortes, and J. Radich
Chronic Myelogenous Leukemia
Hematology,
January 1, 2002;
2002(1):
111 - 135.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. G. Jurcic, S. D. Nimer, D. A. Scheinberg, T. DeBlasio, R. P. Warrell Jr, and W. H. Miller Jr
Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia
Blood,
November 1, 2001;
98(9):
2651 - 2656.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Radich, T. Gooley, E. Bryant, T. Chauncey, R. Clift, L. Beppu, S. Edmands, M. E. D. Flowers, K. Kerkof, R. Nelson, et al.
The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation
Blood,
September 15, 2001;
98(6):
1701 - 1707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kalidas, H. Kantarjian, and M. Talpaz
Chronic Myelogenous Leukemia
JAMA,
August 22, 2001;
286(8):
895 - 898.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Emilia, R. Marasca, P. Zucchini, P. Temperani, M. Luppi, G. Torelli, F. Lanza, C. De Angelis, D. Gandini, G. Castoldi, et al.
BCR-ABL rearrangement is not detectable in essential thrombocythemia
Blood,
April 1, 2001;
97(7):
2187 - 2189.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Olavarria, E. Kanfer, R. Szydlo, J. Kaeda, K. Rezvani, K. Cwynarski, C. Pocock, F. Dazzi, C. Craddock, J. F. Apperley, et al.
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia
Blood,
March 15, 2001;
97(6):
1560 - 1565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Guglielmi, W. Arcese, J. Hermans, A. Bacigalupo, G. Bandini, D. Bunjes, E. Carreras, A. Devergie, F. Frassoni, J. Goldman, et al.
Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis
Blood,
June 1, 2000;
95(11):
3328 - 3334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J.A. ten Bosch, J. H. Kessler, A. M. Joosten, A. A. Bres-Vloemans, A. Geluk, B. C. Godthelp, J. van Bergen, C. J.M. Melief, and O. C. Leeksma
A BCR-ABL Oncoprotein p210b2a2 Fusion Region Sequence Is Recognized by HLA-DR2a Restricted Cytotoxic T Lymphocytes and Presented by HLA-DR Matched Cells Transfected With an Iib2a2 Construct
Blood,
August 1, 1999;
94(3):
1038 - 1045.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Adkins, R. Brown, L. Goodnough, H. Khoury, J. DiPersio, I. Khouri, and R. Champlin
Purine Analog Regimens for Allogeneic Transplant?
J. Clin. Oncol.,
June 1, 1999;
17(6):
1958 - 1960.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Faderl, M. Talpaz, H. M. Kantarjian, and Z. Estrov
Should Polymerase Chain Reaction Analysis to Detect Minimal Residual Disease in Patients With Chronic Myelogenous Leukemia Be Used in Clinical Decision Making?
Blood,
May 1, 1999;
93(9):
2755 - 2759.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Sawyers
Chronic Myeloid Leukemia
N. Engl. J. Med.,
April 29, 1999;
340(17):
1330 - 1340.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P.C. Vincent, L. Rutzen-Loesevitz, B. Tibken, B. Heinze, E.P. Hofer, and T.M. Fliedner
Relapse in Chronic Myeloid Leukemia after Bone Marrow Transplantation: Biomathematical Modeling as a New Approach to Understanding Pathogenesis
Stem Cells,
January 1, 1999;
17(1):
9 - 18.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Moore, D. N. Haylock, J.-P. Levesque, L. A. McDiarmid, L. M. Samels, L. B. To, P. J. Simmons, and T. P. Hughes
Stem Cell Factor as a Single Agent Induces Selective Proliferation of the Philadelphia Chromosome Positive Fraction of Chronic Myeloid Leukemia CD34+ Cells
Blood,
October 1, 1998;
92(7):
2461 - 2470.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Blickstein, A. Aviram, J. Luboshitz, M. Prokocimer, P. Stark, O. Bairey, J. Sulkes, and M. Shaklai
BCR-ABL Transcripts in Bone Marrow Aspirates of Philadelphia-Negative Essential Thrombocythemia Patients: Clinical Presentation
Blood,
October 1, 1997;
90(7):
2768 - 2771.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-T. Kong, K. Ida, H. Ichikawa, K. Shimizu, M. Ohki, N. Maseki, Y. Kaneko, M. Sako, Y. Kobayashi, A. Tojou, et al.
Consistent Detection of TLS/FUS-ERG Chimeric Transcripts in Acute Myeloid Leukemia With t(16; 21)(p11; q22) and Identification of a Novel Transcript
Blood,
August 1, 1997;
90(3):
1192 - 1199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Toren, G Rechavi, and A Nagler
Minimal residual disease post-bone marrow transplantation for hemato- oncological diseases
Stem Cells,
May 1, 1996;
14(3):
300 - 311.
[Abstract]
|
|
|
|
|
|
|
R. P. Warrell, H. de The, Z.-Y. Wang, and L. Degos
Acute Promyelocytic Leukemia
N. Engl. J. Med.,
July 15, 1993;
329(3):
177 - 189.
[Full Text]
|
|
|
|
|
